Bolt Biotherapeutics Q1 revenue drops, net loss narrows

Bolt Biotherapeutics

12/05/2026 21:27

Overview

US cancer immunotherapy developer's Q1 collaboration revenue fell sharply yr/yr

Net loss for Q1 narrowed from prior year due to lower R&D and G&A expenses

Cash balance of $23.9 mln expected to fund operations into 2027

Outlook

Initial clinical data from BDC-4182 Phase 1/2 study expected in 3Q 2026

Cash balance of $23.9 mln expected to fund operations into 2027

Company plans to resume CEA and PD-L1 ISAC programs after BDC-4182 proof-of-concept

Result Drivers

LOWER R&D AND G&A EXPENSES - Co said reduced research and development and general and administrative costs, mainly due to restructuring and lower clinical trial activity, narrowed net loss

Company press release: ID:nGNX7vGdlp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$26,000
Q1 Net Income
-$7.24 mln
Q1 Basic EPS
-$4.31
Q1 Income from Operations
-$7.60 mln
Q1 Operating Expenses
$7.63 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $7.00, about 48.9% above its May 11 closing price of $4.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)